TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03388372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
Study: NCT00069641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iduronate-2-sulfatase enzyme replacement therapy
Description: Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
Study: NCT03273777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drawing of an incision line
Description: Drawing of an incision line prior to skin incision at cesarean section
Study: NCT01634893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with Hydroxychloroquine
Description: dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2.
Study: NCT00069641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iduronate-2-sulfatase enzyme replacement therapy
Description: Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
Study: NCT02014129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally
Study: NCT00069641

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive weekly infusions of placebo.
Study: NCT02014129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally
Study: NCT02186769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal® Consta®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004
Study: NCT01443845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast 500 µg, oral administration, once per day
Study: NCT03766061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Onlay mesh Hernioplasty
Description: Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sublay Mesh Hernioplasty
Description: Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
Study: NCT02921789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleselumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Bolus injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Oral Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Capsules
Description: Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Capsules
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Oral or Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisone
Description: Oral or Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral Tablet
Study: NCT00639951

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A
Description: 20 vials up front in a Single Dose of Antivipmyn

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Antivipmyn ®
Description: 20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
Study: NCT02393859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg/m\^2/day intravenous (IV) on Days 1-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincrisitne
Description: 1.5 mg/m\^2/day IV on Days 1 and 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: 30 mg/m\^2 IV over 24 hours on Day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1 g/m\^2 IV over 36 hours on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: 800 mg/m\^2 IV for 1 hour on Days 2-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-asparaginase
Description: 1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinia-asparaginase
Description: In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
Study: NCT05065658

Intervention type: DRUG
Intervention: Posaconazole
Description: Intravenous posaconazole prophylaxis
Study: NCT03697265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone (UC1010) low dose
Description: Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone (UC1010) high dose
Description: Subcutaneous (SC) administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC) adminstration
Study: NCT04093869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training combined with Exercise (CSTEX)
Description: The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
Study: NCT00845104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT04093869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care plus Education (SOC-ED)
Description: The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
Study: NCT00238875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Procedure/Surgery: stereotactic body radiation therapy
Study: NCT03036774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of antral area
Description: Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasonic measurement of antral area
Description: Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures.
Study: NCT01145131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact or minced beef meat
Description: 135 gram piece of intact or minced beef meat, beef steak or minced beef resp.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact or minced beef meat
Description: 135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
Study: NCT00210899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole medocaril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin plus Ceftazidime
Study: NCT01443845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo, oral administration, once per day.
Study: NCT01477372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Description: Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
Study: NCT03677349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neurorrhaphy
Description: During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1.
Study: NCT03466021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
Study: NCT01571596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
Study: NCT04601129

Intervention type: PROCEDURE
Intervention: enhanced recovery after surgery program
Description: practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
Study: NCT02764411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33% gel
Description: Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
Study: NCT00105534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite
Description: 1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
Study: NCT00802464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
Study: NCT00105534

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
Study: NCT04464239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 Placebo
Description: TS-142 matching placebo tablets
Study: NCT00802464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
Study: NCT03466021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching injection
Study: NCT00073814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol tartrate MDI
Description: levalbuterol MDI 90 mcg QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol MDI
Description: racemic albuterol MDI 180 mcg QID
Study: NCT00802464

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 vaccinations at Months 0 and 2 with placebo
Study: NCT00676325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of Anterior Vaginal Prolapse
Description: seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
Study: NCT01437605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-A3 ASCI injections without Poly IC:LC
Description: MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-A3 ASCI injections with Poly IC:LC
Description: MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
Study: NCT05677061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw with HA-coating (Hiploc)
Description: During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hip Screw without coating (Hiploc)
Description: During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
Study: NCT00567333

Intervention type: OTHER
Group type: OTHER
Intervention: Chiropractic care
Description: A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.

Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary, integrative care
Description: A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
Study: NCT04302805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Privigen
Description: Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymoglobulin
Description: All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
Study: NCT04464239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 Placebo
Description: TS-142 matching placebo tablets
Study: NCT04302805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasma Exchange
Description: All patient will undergo Plasma Exchange before transplantation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: All patient will undergo Plasma Exchange before transplantation.
Study: NCT00676325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.
Description: Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.
Description: Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment for anterior vaginal wall prolapse
Description: Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
Study: NCT01882179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineralocorticoid receptor antagonist potassium-canrenoate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00976794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium plus carbamazepine
Description: Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability
Study: NCT01895023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
Study: NCT00976794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium plus valproate
Description: Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability.
Study: NCT01895023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
Study: NCT03227224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Study: NCT05732896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nociception Leve Indeks
Description: During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
Study: NCT03894241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)
Study: NCT02919826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Dialectical Behaviour Therapy
Description: 12 weekly sessions of DBT group therapy
Study: NCT01974908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrillatory Factor calculation (FF)
Description: During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
Study: NCT00098553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT03109795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: sympathetic nerve activity blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Blood pressure-lowering control condition